Sorrento Therapeutics (NASDAQ:SRNE) and Protalex (OTCMKTS:PRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Volatility & Risk
Sorrento Therapeutics has a beta of 2.64, suggesting that its share price is 164% more volatile than the S&P 500. Comparatively, Protalex has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500.
Valuation and Earnings
This table compares Sorrento Therapeutics and Protalex’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sorrento Therapeutics||$21.19 million||23.49||-$203.54 million||$0.13||31.31|
Protalex has lower revenue, but higher earnings than Sorrento Therapeutics.
Insider and Institutional Ownership
25.6% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Protalex shares are owned by institutional investors. 6.0% of Sorrento Therapeutics shares are owned by insiders. Comparatively, 80.0% of Protalex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Sorrento Therapeutics and Protalex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and recommmendations for Sorrento Therapeutics and Protalex, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sorrento Therapeutics currently has a consensus price target of $20.67, indicating a potential upside of 407.78%. Given Sorrento Therapeutics’ higher probable upside, equities analysts plainly believe Sorrento Therapeutics is more favorable than Protalex.
Sorrento Therapeutics beats Protalex on 6 of the 10 factors compared between the two stocks.
Sorrento Therapeutics Company Profile
Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.
Protalex Company Profile
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.